CA-ASM-GLOBAL
Today, The Rolling Stones have announced they will be extending the STONES TOUR ’24 HACKNEY DIAMONDS with an additional stop in Ridgedale, Missouri, on July 21 at Thunder Ridge Nature Arena. Tickets are on sale Friday, May 31, 2024, at 10 a.m. local time. For ticketing information, please visit www.rollingstones.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523672007/en/
(Graphic: Business Wire)
Mick, Keith and Ronnie kicked off their wildly anticipated tour in Houston, Texas, last month and have brought their legendary show to cities across the United States, including the New Orleans Jazz and Heritage Festival, treating fans to their iconic hits and new music from their critically acclaimed new album HACKNEY DIAMONDS. The STONES TOUR ‘24 HACKNEY DIAMONDS will make stops in 12 more cities across the U.S. and Canada with stops in East Rutherford, Foxboro, Orlando, Atlanta, Philadelphia, Cleveland, Denver, Chicago, Vancouver, Los Angeles and Santa Clara with a final stop in Ridgedale. Full tour routing is below.
Hackney Diamonds is their first studio set of new material since 2005’s A Bigger Bang. Since then, the Stones have continued to smash box office records on a series of global sell-out tours and released 2016’s GRAMMY® Award winning Blue & Lonesome, which featured their brilliant versions of many of the blues tracks that helped shape their sound and topped album charts around the world. In 2022, they thrilled European audiences totaling nearly a quarter of a million on the anniversary Sixty tour. The Rolling Stones have sold over 250 million albums worldwide.
Thunder Ridge Nature Arena — a decade in planning, development and construction with the ambition to create America’s most beautiful outdoor amphitheater — is scheduled to open this May as a one-of-a-kind immersive outdoor “musical postcard from Mother Nature.” Located in Ridgedale, Missouri, just a few miles from Branson, Thunder Ridge Nature Arena is described by its creator and visionary — noted conservationist and Bass Pro Shops founder Johnny Morris as a “gift of the Ozarks to the world.” It is the only venue on Earth completely dedicated to conservation.
AEG Presents’ Concerts West is the promoter of the Stones Tour ’24 Hackney Diamonds. For tickets and information, head to www.rollingstones.com.
THE ROLLING STONES – STONES TOUR ‘24 HACKNEY DIAMONDS
Sponsored by AARP
Thursday, May 23, 2024 |
MetLife Stadium |
East Rutherford, NJ |
Sunday, May 26, 2024 |
MetLife Stadium |
East Rutherford, NJ |
Thursday, May 30, 2024 |
Gillette Stadium |
Foxboro, MA |
Monday, June 3, 2024 |
Camping World Stadium |
Orlando, FL |
Friday, June 7, 2024 |
Mercedes-Benz Stadium |
Atlanta, GA |
Tuesday, June 11, 2024 |
Lincoln Financial Field |
Philadelphia, PA |
Saturday, June 15, 2024 |
Cleveland Browns Stadium |
Cleveland, OH |
Thursday, June 20, 2024 |
Empower Field at Mile High |
Denver, CO |
Thursday, June 27, 2024 |
Soldier Field |
Chicago, IL |
Sunday, June 30, 2024 |
Soldier Field |
Chicago, IL |
Friday, July 5, 2024 |
BC Place |
Vancouver, BC |
Wednesday, July 10, 2024 |
SoFi Stadium |
Los Angeles, CA |
Saturday, July 13, 2024 |
SoFi Stadium |
Los Angeles, CA |
Wednesday, July 17, 2024 |
Levi’s® Stadium |
Santa Clara, CA |
Sunday, July 21, 2024 |
Thunder Ridge Nature Arena |
Ridgedale, MO |
www.youtube.com/user/therollingstones
www.instagram.com/therollingstones
www.tiktok.com/@therollingstones
www.facebook.com/therollingstones
www.twitter.com/rollingstones
www.aegpresents.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523672007/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom